Add like
Add dislike
Add to saved papers

CT Mucus Score and 129Xe MRI Ventilation Defects after 2.5-years anti-IL-5Rα in Eosinophilic Asthma.

Chest 2023 Februrary 12
BACKGROUND: We previously showed in poorly controlled eosinophilic asthma patients that a single dose of benralizumab resulted in significantly improved asthma-control-questionnaire (ACQ-6) score and 129 Xe magnetic-resonance-imaging (MRI) ventilation defect percent (VDP), 28-days post-injection, and 129 Xe MRI VDP and computed tomography (CT) airway mucus occlusions were shown to independently predict this early ACQ-6 response to benralizumab.

RESEARCH QUESTION: Do early VDP responses at 28-days persist and do FEV1 , FeNO and mucus-plug score improve during a 2.5-year treatment period?

STUDY DESIGN AND METHODS: Participants with poorly controlled eosinophilic asthma completed spirometry, ACQ-6 and MRI, 28-days, 1- and 2.5-years post-benralizumab; chest CT was acquired at enrollment and 2.5-years later.

RESULTS: Of 29 participants evaluated at 28-days post-benralizumab, 16 participants returned for follow-up whilst on therapy at 1-year and 13 participants were evaluable whilst on therapy at 2.5-years, post-benralizumab initiation. As compared to 28-days post-benralizumab, ACQ-6 score (2.0±1.4) significantly improved after 1-year (0.5±0.6, p=.02; 95% confidence interval [CI], 0.1-1.1) and 2.5-years (0.5±0.5, p=.03; 95% CI, 0.1-1.1). The mean VDP change at 2.5-years (-4±3%) was greater than the minimal-clinically-important-difference, but not significantly different than VDP measured 28-days post-benralizumab. Mucus-score (3±4) was significantly improved at 2.5-years (1±1, p=.03; 95% CI, 0.3-5.5). In six of eight participants with previous occlusions, mucus-plugs vanished or substantially diminished 2.5-years later. VDP (p<.001) and mucus-score (p<.001) measured at baseline, but not FeNO or FEV1 , independently predicted ACQ-score after 2.5-years.

INTERPRETATION: In poorly controlled eosinophilic asthma, early MRI VDP responses at 28-days post-benralizumab persisted 2.5-years later, alongside significantly improved mucus-score and asthma-control.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app